Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Personalis (Nasdaq: PSNL) reported third-quarter 2026 revenue of $25.596 million, with higher clinical testing volume and a wider net loss. Revenue compared with $14.495 million a year earlier. Clinical diagnostic revenue rose to $4.374 million from $384,000, while delivered clinical tests increased to 13,157 from 4,388. Net loss widened to $33.801 million, or $0.32 per share, from $21.652 million, or $0.24 per share.
Cash, cash equivalents and short-term investments totaled approximately $190.6 million at September 30. Pre-interim results from the prospective B-STRONGER-1 breast cancer study showed 96% baseline detection of circulating tumor DNA and 82% clearance after two cycles of treatment before surgery. Following its July 20 merger agreement with Tempus AI, Personalis will no longer provide financial guidance or hold quarterly earnings calls.
Tempus AI (TEM) reported third-quarter 2026 revenue of $411.5 million, up 23% from the same period in 2025.
Diagnostics revenue rose 20% to $303.5 million, while Data and Applications revenue increased 33% to $108.1 million. Oncology test volume grew 32%. Gross profit increased 27% to $266.7 million. Net loss narrowed to $14.9 million from $80.0 million, including $42.8 million in unrealized securities gains. Adjusted EBITDA rose to $25.6 million from $1.5 million.
Tempus raised its 2026 revenue outlook to $1.60–$1.605 billion and maintained expected adjusted EBITDA of approximately $65 million. October agreements cover oncology data licensing to BMS for up to $137.5 million and Alzheimer's or dementia data licensing to BMS and Pathos for $55 million, each over five years. The pending Personalis acquisition cleared regulatory review; a shareholder approval meeting is planned for November 30, 2026.
Personalis (PSNL) announced that NeXT Personal test data will feature at the ESMO Congress, taking place October 23–27, 2026, in Madrid.
The program includes two oral presentations and two posters. A late-breaking presentation covers updated overall survival and circulating tumor DNA analyses from the C-POST Phase 3 skin cancer trial. A second oral presentation covers pre-interim B-STRONGER-1 results on monitoring tumor DNA during treatment before surgery in early-stage triple-negative breast cancer. The posters address immunotherapy response in advanced cancer and biomarkers associated with survival in platinum-resistant ovarian cancer. No numerical study results were disclosed.
Personalis (Nasdaq: PSNL) commercially launched optional Real-Time Variant Tracker supplemental results for its NeXT Personal test on October 20, 2026.
The addition to the molecular residual disease (MRD) test report tracks clinically relevant resistance mutations and therapeutically targetable variants over time during NeXT Personal testing. It includes variants with established clinical significance, including associations with FDA-approved therapies and recommendations in National Comprehensive Cancer Network guidelines.
Personalis (Nasdaq: PSNL) reported Q2 2026 revenue of $22.4 million, up 30% year over year, driven by pharma testing services and a surge in clinical testing.
Clinical test volume rose 199% to 10,384 tests and clinical revenue increased 442% to $2.6 million, helped by expanded Medicare reimbursement.
Pharma testing and other customer revenue grew 51% to $16.8 million, while population sequencing (VA MVP) declined 9% to $3.0 million.
The company reported a net loss of $31.7 million for Q2 and ended the quarter with about $212.7 million in cash, cash equivalents and short-term investments. Following a signed merger agreement with Tempus AI announced July 20, 2026, Personalis will no longer provide financial guidance or hold quarterly earnings calls.
Tempus AI (NASDAQ: TEM) has entered a definitive agreement to acquire Personalis (NASDAQ: PSNL), valuing Personalis at an enterprise value of $1.5 billion net of Tempus’ existing stake. Personalis shareholders will receive $16.25 per share, a 6% premium to the prior Friday close and 28% to the unaffected 30‑day VWAP.
The deal is structured as a 100% stock transaction, with Tempus able to elect up to 50% of consideration in cash, financed by cash on hand and borrowings under existing credit facilities. Personalis holders will receive a floating exchange ratio of Tempus shares, capped at 0.3356 per Personalis share, to be finalized closer to closing.
The acquisition integrates Personalis’ tumor‑informed NeXT Personal MRD technology, which has Medicare coverage in three indications, into Tempus’ AI‑enabled precision oncology and multimodal data platform. According to Tempus, this expands its capabilities across the cancer care continuum and positions both companies in the emerging $20 billion MRD market. Closing is expected in late 2026 or early 2027, subject to Personalis shareholder and regulatory approvals. Personalis reported preliminary Q2 revenue of $22.4 million and delivered 10,384 clinical tests, a 33% sequential test volume increase.
Personalis (Nasdaq: PSNL) announced it has achieved UKCA marking for its NeXT Personal Dx test, enabling clinical use of its ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, including England, Wales, and Scotland.
According to Personalis, UKCA marking confirms the test meets UK safety, health, and performance standards, supports its regulatory readiness, and allows multinational biopharma trials to use the same clinical-grade MRD platform across US and UK sites. The company said NeXT Personal Dx offers high sensitivity for circulating tumor DNA to track treatment response, detect residual disease, and identify early recurrence. Personalis has appointed Link Medical Solutions in London as its business partner to support commercialization and expand access to personalized MRD testing in Great Britain.
Personalis (Nasdaq: PSNL) announced its EDTA Blood Collection Kit and cfDNA Blood Collection Kit have received Class A CE-IVD marking under the EU IVDR. This clearance allows use in interventional clinical trials across the European Union and Great Britain, supporting deployment of NeXT Personal MRD testing for global drug development.
Personalis (Nasdaq: PSNL) reported new ASCO 2026 data showing its NeXT Personal MRD test delivers ultrasensitive ctDNA detection across six solid tumors, including colorectal, lung, ovarian, endometrial, melanoma and renal cell cancers.
Results highlight early relapse detection, high sensitivity and strong prognostic value across multiple clinical settings.
Personalis (Nasdaq: PSNL) will feature six clinical abstracts using its NeXT Personal ultra-sensitive ctDNA test at the ASCO 2026 Annual Meeting, May 29–June 2 in Chicago.
Data span six solid tumor types, including a TRACERx podium talk on single-digit parts-per-million ctDNA detection in early-stage NSCLC.